Table 1.
Baseline patient characteristics. Values are presented as mean ± SD, number of patients (percent), or median (IQR) for NT-proBNP.
| All (N = 61) | ICMP (N = 19) | DCMP (N = 42) | p | |
|---|---|---|---|---|
| Age (y) | 52 ± 12 | 55 ± 8 | 51 ± 10 | 0.16 |
| Male gender (%) | 51 (83) | 15 (79) | 36 (85) | 0.54 |
| LVEF (%) | 30 ± 6 | 29 ± 6 | 30 ± 5 | 0.41 |
| 6MWT (m) | 482 ± 82 | 475 ± 82 | 486 ± 83 | 0.92 |
| NT-proBNP (pg/mL (IQR)) | 1132 (350-2279) | 1133 (394-2239) | 1127 (333-2359) | 0.99 |
| Creatinine (mmol/L) | 86 ± 23 | 89 ± 21 | 84 ± 24 | 0.52 |
| Bilirubin (μmol/L) | 16 ± 8 | 16 ± 6 | 17 ± 9 | 0.75 |
| Sodium (mmol/L) | 140 ± 2 | 140 ± 3 | 141 ± 2 | 0.63 |
| AST (μmol/L) | 0.5 ± 0.1 | 0.45 ± 0.14 | 0.47 ± 0.14 | 0.62 |
| AF (μmol/L) | 1.2 ± 0.4 | 1.21 ± 0.33 | 1.13 ± 0.39 | 0.39 |
| gGT (μmol/L) | 1.1 ± 1.4 | 0.68 ± 0.38 | 1.2 ± 1.4 | 0.10 |
| RDW (%) | 13.7 ± 1.2 | 13.7 ± 1.1 | 13.7 ± 1.2 | 0.92 |
| Leukocytes (×109) | 7.1 ± 1.6 | 6.9 ± 1.4 | 7.2 ± 1.6 | 0.47 |
| Hemoglobin (g/L) | 144 ± 11 | 146 ± 10 | 143 ± 12 | 0.32 |
| Platelet count (×109) | 208 ± 49 | 198 ± 34 | 213 ± 53 | 0.27 |
| Medical management | ||||
| ACEI/ARB | 61 (100) | 19 (100) | 42 (100) | / |
| Beta blockers | 61 (100) | 19 (100) | 42 (100) | / |
| MRA | 61 (100) | 19 (100) | 42 (100) | / |
| Diuretic | 33 (54) | 12 (63) | 21 (51) | 0.34 |
| Aspirin | 21 (34) | 19 (100) | 2 (4) | <0.05 |
| Galectin-3 levels (ng/mL) | ||||
| Baseline | 13.4 ± 5.5 | 15.1 ± 7.2 | 12.7 ± 4.3 | 0.12 |
| 3 months | 13.1 ± 5.8 | 13.3 ± 5.8 | 12.4 ± 5.8 | 0.83 |
ICMP: ischemic cardiomyopathy; DCMP: nonischemic cardiomyopathy; LVEF: left ventricular ejection fraction; 6MWT: 6-minute walk test; AST: aspartate transaminase; AF: alkaline phosphatase; gGT: γ-glutamyltranspeptidase; RDW: red cell distribution width; ACEI: angiotensin convertase inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist.